MK-677 Dosagem: 10-25mg Before Bed, Why Timing (2026)

Bedtime dosing syncs with natural GH pulses — morning dosing fights them. Covers 8-12 week cycles, appetite management, and blood sugar.

MK-677 (ibutamoren) is a non-peptide growth hormone secretagogue that mimics ghrelin to stimulate natural GH release. Unlike true peptides, it's orally bioavailable — no injection required. Clinical trials with human data span up to 2 years of continuous use. This is not medical advice.

Research-context information only. MK-677 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Community Protocol

MK-677 has no standardized clinical dosing protocol — this is a community protocol directly informed by clinical trial data (25 mg daily used in major studies).

For the full MK-677 profile, vendor pricing, and stack protocols, see our MK-677 peptide page .

Cycling Details

Documented protocols begin at 10 mg daily for weeks 1-2 to assess tolerance. Appetite increase and water retention are most pronounced in the first 1-2 weeks. Protocols then progress to 15-25 mg daily based on response — community reports cluster around 20-25 mg for GH stimulation.

The 8-12 week on / 4 week off cycle prevents receptor desensitization, though the 2-year Nass study showed sustained effects with continuous use. MK-677's ~24 hour half-life means levels reach steady state quickly and clear within days of discontinuation.

Why before bed: Natural GH release peaks during deep sleep. Bedtime dosing aligns with this rhythm, may enhance sleep quality, and mitigates daytime appetite stimulation.

Routes of Administration

Oral (only route): MK-677 has excellent oral bioavailability (~60-70%) due to its non-peptide structure — it survives stomach acid intact. Liquid solutions (1 mL dropper dosing) are most common. Capsules provide standardized dosing. Sublingual absorption is also effective but unnecessary given oral bioavailability.

Reconstitution Quick Reference

No reconstitution needed — MK-677 is taken orally as a pre-mixed liquid solution or capsule. Community protocols describe dosing via the included volumetric dropper per the product's markings, or per capsule labeling.

How much will this cycle cost?

Calculate your total cost including vials, syringes, and supplies

Ready to buy? See our MK-677 buying guide for format comparison, COA verification, and pricing.

Where These Numbers Come From

MK-677 has substantial human clinical data — rare for a non-FDA-approved GH compound.

Murphy et al. (1998) showed 25 mg daily reversed diet-induced catabolism and significantly increased GH and IGF-1 levels (PMID 9467534). The landmark Nass et al. (2008) 2-year study using 25 mg daily demonstrated sustained increases in GH, IGF-1, and lean body mass with an acceptable safety profile (PMID 18981485).

This is rare in the peptide world — community doses directly mirror clinical trial dosing. 25 mg daily was the standard efficacy dose, 10 mg showed activity with diminished returns, and doses above 50 mg showed no additional benefit but increased side effects.

Stacking Protocols

MK-677's oral route means no injection site competition. It can run longer cycles than most injectables. Community protocols and trial oversight commonly describe closer blood sugar monitoring when combining multiple GH compounds.

Side Effects & Safety

• Increased appetite — reported in the majority of trial subjects (Murphy et al., PMID 9467534 ), commonly pronounced in the first 1-2 weeks per community sources
• Water retention/edema — mild to moderate; community sources describe it subsiding after 2-4 weeks
• Mild insulin resistance — temporary and reversible upon discontinuation (Nass et al., PMID 18981485 )
• Lethargy/fatigue — community sources report this especially in the first 2-3 weeks
• Joint stiffness — from water retention, community sources describe it as usually mild
• Elevated prolactin — community sources report this in some individuals, typically not clinically significant
• Carpal tunnel symptoms — rare, from water retention

Long-term safety (2-year Nass study): No significant changes in prostate, cardiovascular markers, or cancer incidence. The Nass et al. 2-year study described reversible mild insulin resistance and resolution toward baseline GH parameters within weeks of discontinuation.

Managing sides: Community protocols describe beginning at 10 mg, dosing before bed, managing carbohydrate intake for insulin sensitivity, and staying hydrated.

Frequently Asked Questions

Related Guides

• MK-677 peptide page — vendor pricing and full compound profile
• MK-677 Benefits Guide — GH elevation, sleep, and body composition effects
• MK-677 Results Timeline — week-by-week expectations from day 1 through month 6
• Ipamorelin Dosing Guide — injectable GHRP alternative
• CJC-1295 + Ipamorelin Stack Guide — GHRH/GHRP stacking with MK-677
• GHRP-2 Dosing Guide — injectable GH secretagogue
• Calculate Your MK-677 Cycle Cost — estimate cost for your protocol
• Best Peptides for Muscle Growth (2026) — all 10 muscle-building peptides ranked
• MK-677 Buying Guide — oral capsule sourcing, COA red flags, vial pricing

References

For educational and research purposes only. This is not medical advice. MK-677 is not FDA-approved for any indication and is sold as a research chemical.

Tabelas de referência

Perguntas frequentes

What doses do clinical trials and community sources report for MK-677?

The most common community protocol is 10-25 mg taken orally before bed, daily for 8-12 weeks followed by 4 weeks off. This aligns with clinical studies that used 25 mg daily.

Why is MK-677 taken at night?

Natural GH release peaks during deep sleep. Taking MK-677 before bed aligns with this natural rhythm and may enhance sleep quality. It also helps mitigate appetite stimulation while you're sleeping.

What cycle lengths do documented protocols describe for MK-677?

Common protocols are 8-12 weeks on, 4 weeks off. Longer cycles (6+ months) are used but may lead to desensitization. The 2-year Nass study showed sustained effects, but community protocols commonly cycle.

What stacking protocols are documented for MK-677 and other peptides?

Documented protocols pair MK-677 with other GH-related peptides like ipamorelin or CJC-1295. Since it works via ghrelin receptors while others work via GHRH, the mechanisms are complementary.

Do documented protocols cycle MK-677?

While not strictly necessary (clinical studies ran for 2+ years), community protocols typically describe 8-12 weeks on / 4 weeks off to limit receptor desensitization, though the Nass 2-year study documented sustained effects with continuous use.

Will MK-677 show up on drug tests?

MK-677 is prohibited by WADA and may be tested for in athletic competitions. It's not typically tested for in standard employment drug screens, but specialized tests can detect it.